Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Completed · Phase 4

Conditions studied: Ankylosing Spondylitis

In brief

This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Key facts

Study ID
NCT03350815
Run by
Novartis Pharmaceuticals
People needed
322
Starts
2018-03-13
Expected to finish
2021-05-29
Last updated by the study team
2022-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.